Applicable Grid:
|
Breast Cancer |
Breast Cancer miRNA Plate Assay Kit I |
miR-125a, miR-125b, miR-145, miR-146, miR-205, miR-206, miR-155, U6 |
|
Breast Cancer miRNA Plate Assay Kit II |
miR-21, miR-10b, let7, miR-27b, miR-17-5p, miR-9-1, miR-126, U6 |
|
|
Breast Cancer miRNA Plate Assay Kit III |
miR-200, miR-210, miR-335, miR-373, miR-520c, U6 |
|
|
Lung Cancer |
Lung Cancer miRNA Plate Assay I |
let-7, miR-29, miR-34, miR-128b, miR-155, miR-200c, miR-221, U6 |
|
Lung Cancer miRNA Plate Assay II |
miR-17-92 cluste |
|
|
Colorectal Cancer |
Colorectal Cancer miRNA Plate Assay I |
miR-31, miR-96, miR-133b, miR-135b, miR-143, miR-145, miR-183, U6 |
|
Colorectal Cancer miRNA Plate Assay II |
miR-17-92 cluster |
|
|
Colorectal Cancer miRNA Plate Assay III |
let-7a, let-7b, miR-15b, miR-21, miR-26a, miR-30a, miR-30c, U6 |
|
|
Colorectal Cancer miRNA Plate Assay IV |
miR-18, miR-27a, miR-34b, miR-106, miR-181b, miR-200c, miR-342, U6 |
|
|
Liver Cancer |
Liver Cancer miRNA Plate Assay I |
let-7c, miR-21, miR-23a, miR-24, miR-27a, miR-34a, miR-122a, U6 |
|
Liver Cancer miRNA Plate Assay II |
miR-125a, miR-141, miR-199a, miR-200b, miR-221, miR-224, miR-320, U6 |
|
|
Pancreatic Cancer |
Pancreatic Cancer miRNA Plate Assay I |
miR-34a, miR-21, miR-155, miR-204, miR-221, miR-222, miR-301, U6 |
|
Pancreatic Cancer miRNA Plate Assay II |
miR-155, miR-133a, miR-196a, miR-216, miR-217, miR-196b, miR-376a, U6 |
|
|
Bladder Cancer |
Bladder Cancer miRNA Plate Assay I |
miR-17; miR-23a, miR-23b; miR-26b; miR-103-1; miR-185; miR-203, U6 |
|
Ovarian Cancer |
Ovarian Cancer miRNA Plate Assay I |
let-7a-3, let-7b, miR-9, miR-18a, miR-93, miR-141, miR-199a, RNU48 |
|
Ovarian Cancer miRNA Plate Assay II |
miR-100, miR-124a, miR-125b, miR-140, miR-141, miR-145, miR-199a, U6 |
|
|
Ovarian Cancer miRNA Plate Assay III |
miR-200a, miR-200b, miR-200c, miR-214, miR-302, miR-223, miR-429, RNU48 |
|
|
Prostate Cancer |
Prostate Cancer miRNA Plate Assay I |
let-7c, miR-34, miR-125b, miR-126, miR-145, miR-146a, miR-143, U6 |
|
Thyroid Cancer
|
Thyroid Cancer miRNA Plate Assay I |
miR-21, miR-31, miR-221, miR-222, miR-181b, miR-221, miR-222, U6 |
|
Thyroid Cancer miRNA Plate Assay II |
miR-30a, miR-30d; miR-125b; miR-26a, miR-197, miR-346, miR-138, U6 |
|
|
Lymphoma
|
Lymphoma miRNA Plate Assay I |
let-7a, miR-16-1, miR-17, miR-21, miR-96, miR-106a, miR-155, U6 |
|
Lymphoma miRNA Plate Assay II |
miR-17-92 clust |
|
|
Leukemia |
Leukemia miRNA Plate Assay I |
let-7, miR-15, miR-16, miR-29, miR-142, miR-155, miR-181,U6 |
|
Leukemia miRNA Plate Assay II |
miR-17-92 cluster |
|
|
Leukemia miRNA Plate Assay III |
miR-106-363 cluster |
|
|
Leukemia miRNA Plate Assay IV |
miR-107, miR-150, miR-181a, miR-181b, miR-128a, miR-128b, miR-223, U6 |
|
|
Leukemia miRNA Plate Assay V |
miR-10a, miR-10b; miR-20a, miR-143, miR-145, miR-196a-1, miR-342, U6 |
Principle
In the proprietary miRNA plate assay, one miRNA molecule is flanked by a capture oligo and a biotinated detection oligo through two bridges oligos. One of the bridge oligos is partially hybridized with the miRNA molecule and the capture oligo and another with the miRNA and the detection oligo. The hybrid is immobilized onto plate through hybridization with an immobilized oligo and detected by a streptavidin-HRP conjugate and chemiluminecscent substrate. This hybrid structure is sensitive to the sequence of the miRNA molecule. One nucleotide difference will prevent the formation of the hybrid and therefore miRNA isoform can be differentiated, which normally is hard to tackle with Northern blot. In addition, the sensitivity of the assay is higher than miRNA Northern blot assay..gif)
